Medical blog » announces

Daxor Announces Tahlequah City Hospital of Tahlequah, OK Acquires …

admin — Fri, 09 Jan 2009 01:03:50 +0000

Daxor Corporation (AMEX: DXR), a medical
instrumentation and biotechnology company, today announced the receipt of a
signed trial agreement from Tahlequah City Hospital of Tahlequah, Oklahoma.
Tahlequah City Hospital (TCH) is a 100-bed rural hospital with a strategic
plan designed to turn TCH into a regional healthcare center. By recruiting
top physicians in their respective field and acquiring state-of-the-art
technology, TCH has already implemented a cardiovascular open-heart surgery
program and a comprehensive nephrology program including dialysis services.
Dr. James Madison, TCH’s Director of Nephrology, noted that, “Tahlequah’s
patient population is over-represented in the area of kidney disease. With
the high incidence of diabetes and hypertension we are using sophisticated
techniques to support the needs of our open-heart and nephrology patients.
I’ve seen the benefit of treating patients based upon an intravascular
blood volume measurement, which is why the inclusion of this service is an
important adjunct to our program and demonstrates TCH’s commitment to
providing the best of care.”
Dr. Joseph Feldschuh, Daxor’s C.E.O. and a practicing cardiologist, stated
that, “The use of the BVA-100 by Tahlequah City Hospital is a critical step
forward to improving the care of renal dialysis patients, who undergo major
changes in blood volume during their course of dialysis. It is expected
that utilization of the BVA-100 will enable physicians to provide a more
precise dialysis treatment.”
Daxor’s Blood Volume Analyzer BVA-100 will be located within TCH’s Nuclear
Medicine Department and will be utilized to diagnose a variety of patient
blood volume derangements.
Daxor Corporation manufactures and markets the BVA-100, a semi-automated
Blood Volume Analyzer. The BVA-100 is used in conjunction with Volumex,
Daxor’s single use diagnostic kit. For more information regarding Daxor
Corporation’s Blood Volume Analyzer BVA-100, visit Daxor’s website
.
Contact Information:
Stephen Feldschuh
Chief Operating Officer
212-330-8515
stephen@daxor.com
or
Diane Meegan
Investor Relations
212-330-8512
dmeegan@daxor.com

American Medical Systems Announces Management Change

admin — Wed, 07 Jan 2009 09:25:48 +0000

American Medical Systems, headquartered in Minnetonka, Minn., is a
diversified supplier of medical devices and procedures to cure erectile
dysfunction, benign prostate hyperplasia, incontinence, menorrhagia,
prolapse and other pelvic disorders in men and women. These disorders
can significantly diminish one’s quality of life and profoundly affect
social relationships. In recent years, the number of people seeking
treatment has increased markedly as a result of longer lives,
higher-quality-of-life expectations and greater awareness of new
treatment alternatives. American Medical Systems’ products reduce or
eliminate the incapacitating effects of these diseases, often through
minimally invasive therapies. The Company’s products were used to treat
approximately 320,000 patients in 2008.

Cambridge Health Alliance announces steep cuts

admin — Sun, 07 Dec 2008 18:56:07 +0000

will lose 12 percent of its staff through a combination of layoffs, attrition and retirements. CHA will close six community health centers and will stop admitting patients overnight to
, although emergency services there will remain available. Officials there said the magnitude of current and future financing challenges, coupled with the soured economy have put their whole system in jeopardy, forcing the cuts.
“While extremely challenging and difficult for us all, by taking swift action now we hope to transform Cambridge Health Alliance’s health care system in a way that continues our mission of excellence,” said Mary Cassesso, chair of the CHA board of directors, in a statement.
will close by March 31. Inpatient medicine and surgery at Somerville Hospital will cease by June 15. Two of the eight psychiatry units will close, while one unit at Somerville hospital will move to
in Everett and another will move from Somerville to Cambridge Hospital. The plan also includes a hiring freeze and a capital spending freeze, an elimination of travel, and no raises for system executives.
Massachusetts Secretary of Health and Human Services Judy Ann Bigby said in a statement that, “For the past few months, we have been working with Cambridge Health Alliance to develop a shared understanding of the essential services they provide and explore ways we can work together to ensure the hospital’s long-term sustainability.”
CHA has scheduled several public forums Feb. 4-6 to review the impact on services. Officials said the goal of the plan is to provide for the most critical health care needs, while consolidating services to achieve economies of scale.

Quantum Health Announces Holiday Contest: Win a Complete Natural …

admin — Wed, 05 Nov 2008 13:53:37 +0000

A contest, or sweepstakes, give away from Quantum Health is open for entries. Grand prize is 19 Natural Health Reference and How-to Books, comprising a Complete Home Health Library. Five Second prizes are the 896 page Prescription for Healing by Phyllis Balch.
Eugene, OR (PRWEB) November 17, 2008 — Quantum Health announced it's holiday sweepstakes featuring a grand prize of 19 natural health reference and how-to books worth about $500. The Win a Complete Natural Home Health Library focuses on natural healing. These books, selected by the editors of It's Your Health newsletter, cover: natural treatments and remedies; symptoms and conditions; herb, vitamin and supplement reference works; drug/supplement interaction guides – how specific prescription drugs mix with specific supplements, and much, more.
To enter, go here:
Plus five second prize winners will receive the 896 page “Prescription for Natural Healing” by Phyllis Blach.
All entrants will automatically receive an online coupon good for 10% any Quantum Health order, plus a free subscription to It's Your Health.
Entries can be made online or by mail. The contest is open to US and Canadian residents only and the winner will be chosen on January 15, 2009. No purchase is necessary.
Prescription for Nutritional Healing, 4th Edition by Phyllis A. Balch Retail Value $24.95
Prescription for Drug Alternatives: All-Natural Options for Better Health without the Side Effects by James Balch Retail Value $24.95
Natural Health, Natural Medicine: The Complete Guide to Wellness and Self-Care for Optimum Health by Andrew Weil Retail Value $14
PDR for Nonprescription Drugs, Dietary Supplements, and Herbs 2009 by PHYSICIANS DESK REFERENCE Inc. Retail Value $59.95)
The Complete Idiot's Guide to Vitamins and Minerals, 3rd Edition (Complete Idiot's Guide to) by D.C., Ph.D., C.C.N., Alan H. Presman (Author), Sheila Buff Retail Value $18.95
The PDR Pocket Guide to Prescription Drugs, 8th Edition (EAN): 8th Edition) by Thompson PDR Retail Value $8.50
A-Z Guide to Drug-Herb-Vitamin Interactions Revised and Expanded 2nd Edition: Improve Your Health and Avoid Side Effects When Using Common Medications and Natural Supplements Together by Alan R. Md Gaby, Inc. Healthnotes Retail Value $22.95
Our Bodies, Ourselves: A New Edition for a New Era by Boston Women's Health Book Collective, Judy Norsigian Retail Value $26
Women's Encyclopedia of Natural Medicine by Tori Hudson Retail Value $24.95
The Harvard Medical School Guide to Men's Health: Lessons from the Harvard Men's Health Studies by Harvey B. Simon Retail Value $15
Child Health Guide: Holistic Pediatrics for Parents by Randall Neustaedter Retail Value $17.95
Your Child's Health: The Parents' One-Stop Reference Guide to: Symptoms, Emergencies, Common Illnesses, Behavior Problems, and Healthy Development by Barton D. Schmitt Retail Value $20
You: On A Diet: The Owner's Manual for Waist Management by Mehmet C. Oz, Michael F. Roizen Retail Value $25
Eat This Not That!: Thousands of Simple Food Swaps That Can Save You 10, 20, 30 Pounds-or More! by David Zinczenko, Matt Goulding Retail Value $19.95
You: Staying Young: The Owner's Manual for Extending Your Warranty (You) by Michael F. Roizen, Mehmet C. Oz Retail Value $26
Brain Longevity: The Breakthrough Medical Program that Improves Your Mind and Memory by Dharma Singh Khalsa, Cameron Stauth Retail Value $14.95
Healthy Child Healthy World: Creating a Cleaner, Greener, Safer Home by Christopher Gavigan Retail Value $25.95
150 Most Effective Ways to Boost Your Energy: The Surprising, Unbiased Truth About Using Nutrition, Exercise, Supplements, Stress Relief, and Personal Empowerment to Stay Energized All Day by Jonny Bowden Retail Value $24.95
Quantum, Inc. — Natural Products That Make a Difference — Quantum is a natural product company founded in 1981 that specializes in unique formulations designed to help people feel and look their best. Key categories include cold sore treatments, canker sore treatments, cold and flu relief, natural insect repellents, Quantum Derma skin healing botanicals, dry mouth and immune support. Based in Eugene, OR, Quantum's makes over 50 products which are distributed throughout the United States and Canada and on the Internet. For more information, call toll-free at 1-800-448-1448 or visit
.

http://www.prweb.com/pingpr.php/U3F1YS1NYWduLVBpZ2ctSG9yci1UaGlyLVNpbmctWmVybw==

Wound Management Technologies, Inc. Announces FDA Clearance of 510k

admin — Wed, 05 Nov 2008 08:43:28 +0000

FORT WORTH, Texas, Nov. 13 TX-WoundMgmtFDAclears

FORT WORTH, Texas, Nov. 13 /PRNewswire-FirstCall/ — Wound Care
Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., (OTC
Bulletin Board: WNDM), announced today the 510k clearance of a new wound
management product utilizing their patented hydrolyzed collagen technology.

The new addition to our product line (patent pending) combines hydrolyzed
collagen with the healing properties of polysulfated glycosaminoglycan (PSGAG)
and will initially be available in gel form. PSGAG enhances the absorptive
capacity of the hydrolyzed collagen gel, making it appropriate for the
management of exudative wounds. In addition, PSGAG has been shown to prepare
the granulation tissue for epidermal migration by maintaining a uniform, low
density granulation tissue more easily modified by the migrating epithelium
thus improving the rate of epithelialization of a chronic wound and reducing
scarring.

The product has been cleared and is indicated for topical use in the
management of chronic and acute wounds and dermal ulcers including the
management of:

– Pressure Ulcers (Stages I-IV)
– Venous Stasis Ulcers
– Diabetic Ulcers
– First and Second Degree Burns
– Surgical Wounds
– Traumatic wounds
– Superficial Wounds
– Ulcers resulting from arterial insufficiency
– Grafted wounds and donor sites
“We are delighted with the FDA clearance of the hydrolyzed collagen with
polysulfated glycosaminoglycan (PSGAG),” states
, President of
Wound Care Innovations. “This allows us to bring to the high margin, advanced
wound care market, a product that utilizes our proven, patented hydrolyzed
collagen and incorporates the distinctive characteristics of PSGAG to prepare
the wound bed for re-epithelialization, wound closure.”
Costs associated with wound care are significant, exceeding billions of
dollars annually. “We are introducing a new, improved product which addresses
the epithelialization of healing wounds and will be cost effective, patient
ready and easy to use in all health care settings. The product is cost
effective both in terms of direct and indirect costs. We are encouraged by
initial test observations which promise improved clinical outcomes for the
patient. Our expectations are high. We expect our hydrolyzed collagen with
Polysulfated Glycosaminoglycan to contribute significantly to our growth
moving forward.”
About Wound Management Technologies, Inc.:
Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM), with its
corporate headquarters in
Fort Worth, Texas
, markets and distributes wound
care products to the healthcare market under patented technology licensed to
the Company. The Company is positioned and seeks to be a leading provider of
wound care products. For more information on the Company please visit the
Company’s Website at
.
“Safe Harbor” Statement: Under The Private Securities Litigation Reform
Act of 1995: The statements in the press release that relate to the company’s
expectations with regard to the future impact on the company’s results from
new products in development are “forward-looking statements,” within the
meaning of the Private Securities Litigation Reform Act of 1995. Since this
information may contain statements that involve risk and uncertainties and are
subject to change at any time, the company’s actual results may differ
materially from expected results. This document may contain forward-looking
statements concerning the Company’s operations, current and future performance
and financial condition. These items involve risks and uncertainties such as
product demand, market and customer acceptance, the effect of economic
conditions, competition, pricing, the ability to consummate and integrate
acquisitions, and other risks and uncertainties detailed in the Company’s SEC
filings. The Company undertakes no obligation to revise any of these
statements to reflect the future circumstances or the occurrence of
unanticipated events.
SOURCE Wound Management Technologies, Inc.

Electro-Optical Sciences Announces Positive Top-Line Results From …

admin — Thu, 30 Oct 2008 04:19:12 +0000

Electro-Optical Sciences, Inc. (“EOS”)
(NASDAQ: MELA) today announced positive top-line results of its pivotal
trial of MelaFind, a non-invasive, point-of-care instrument to assist in
the early detection of melanoma, the deadliest form of skin cancer. The
blinded study, conducted at seven centers across the US, included 1,831
pigmented skin lesions from 1,383 patients, making this the largest
prospective study ever conducted in melanoma detection. EOS is working to
complete its Pre-Market Approval (PMA) application and expects to file it
with the US Food and Drug Administration (FDA) shortly.
“MelaFind appears to be an excellent tool to help detect melanoma at the
earliest, most treatable stage,” said Gary D. Monheit, MD, Associate
Clinical Professor of Dermatology at the University of Alabama in
Birmingham and the lead investigator for the MelaFind pivotal trial. “With
no cure for late stage melanoma, early detection is our best defense
against this cancer, which has reached epidemic proportions.”
Prior to the start of the study, EOS and the FDA entered into a binding
protocol agreement to stipulate the sensitivity and specificity endpoints
that should be used to determine the safety and effectiveness of MelaFind.
MelaFind detected 112 of 114 (98% sensitivity; lower confidence bound of
95%) melanomas that were eligible and evaluable for primary sensitivity
endpoint analysis, and 125 of 127 (98% sensitivity; lower confidence bound
greater than 95%) melanomas overall. The protocol agreement calls for
sensitivity endpoints of greater than 95% lower confidence bound(footnote
1).
MelaFind’s specificity, the ability to accurately rule out disease, was
significantly superior (9.5%) to that of the study dermatologists (3.7%),
who are skin cancer experts (p-value less than 0.02). The protocol
agreement calls for MelaFind to be more specific than the study physicians
at a p-value(footnote 2) of less than 0.05.
Almost half of the melanomas in the study were melanoma in situ, the most
curable yet most difficult form of melanoma to detect.
“These clinically compelling data suggest that MelaFind may help detect
melanoma earlier, and more accurately differentiate many of the
non-malignant lesions that mimic melanoma,” said Darrell Rigel, MD,
Clinical Professor of Dermatology at New York University Medical School.
“This should lead to improved biopsy efficiency and help reduce the number
of unnecessary biopsies, which can be painful and scarring.”
The skin cancer experts who participated in this study had previously made
the decision to biopsy all 1,831 pigmented skin lesions prior to enrolling
the patients in the MelaFind clinical trial.
In order to generate a comparison with dermatologists’ ability to
accurately detect melanoma, EOS conducted a parallel pilot readers’ study
with a different group of 39 dermatologists. Using images and clinical
histories of 23 randomly-selected melanomas from the pivotal study, this
group of dermatologists, on average, would have decided to biopsy only
approximately 18 (80%) of the melanomas, whereas the MelaFind result would
have led to a biopsy of 22 of the melanomas (biopsy sensitivity of 96%). A
larger readers’ study to provide additional data regarding the sensitivity
of MelaFind relative to physicians will commence shortly. Data from these
studies will be submitted to the FDA.
“We are extremely pleased with the outcome of the pivotal study and are now
focused on completing our PMA to submit to the FDA as quickly as possible,”
said Joseph V. Gulfo, MD, President and CEO of EOS. “Our mission with
MelaFind has always been to provide a useful tool to aid in detecting
melanoma at its earliest, most curable stage. We look forward to discussing
these data with the agency.”
The company chose the final classification algorithm based on its success
at identifying melanomas in a series of large, blinded and sequential
internal classifier selection studies conducted immediately prior to the
analysis of the pivotal trial data. Including the pivotal trial, the
MelaFind classifier successfully detected 430 of the 432 melanomas against
which it was tested.
There were no adverse events associated with the use of MelaFind.
The FDA has notified EOS that the MelaFind PMA will receive Expedited
Review once the application is submitted. EOS plans to submit the findings
from the pivotal study and the readers’ studies to peer-reviewed journals
for publication.
MelaFind uses 10 different wavelengths of light to see where a clinician
cannot — up to 2.5 millimeters below the skin’s surface. Using advanced
algorithms, trained and developed on a database of 9,000 pigmented skin
lesions and over 600 melanomas, including those from the pivotal study, the
system provides an immediate result that informs the decision to biopsy.
EOS will host a conference call on Friday, February 13 at 8:30 am EST. To
participate, please dial 800-299-7089 fifteen minutes before the conference
is scheduled to begin. Callers outside of the U.S. should dial
+617-801-9714. The conference call passcode is “Electro Optical Sciences.”
A live webcast of this call will be available in the investor relations
section of
. A webcast replay of the call will be
available for one month on the company’s website, or until February 27,
2009 by dialing
888-286-8010. Callers outside of the US should dial +617-801-6888. The
replay participant code is 52141913.
Melanoma is the deadliest form of skin cancer, responsible for
approximately 80% of skin cancer fatalities. The melanoma rate has
continued to increase with an estimated 120,000 new cases projected in
2009. A recent National Cancer Institute report published in the July 10
online edition of the Journal of Investigative Dermatology indicates that
annual incidence of melanoma among young adult Caucasian women rose 50%
between 1980 and 2004. Melanoma is the most common cancer in women age 25
to 29 and the number one cancer killer of women age 30 to 35. Although no
cure is currently available for advanced-stage melanoma, if caught early,
melanoma is virtually 100% curable.
EOS is a medical device company focused on designing and developing a
non-invasive, point-of-care instrument to assist in the early detection of
melanoma. MelaFind features a hand-held imaging device that emits light of
multiple wavelengths to capture images of suspicious pigmented skin lesions
and extract data. Using sophisticated algorithms, the data are then
analyzed against a proprietary database of melanomas and benign lesions in
order to provide information to assist in the determination of whether the
lesion should be biopsied.
For more information on EOS, visit
.
This press release includes “forward-looking statements” within the meaning
of the Securities Litigation Reform Act of 1995. These statements include
but are not limited to our plans, objectives, expectations and intentions
and other statements that contain words such as “expects,” “contemplates,”
“anticipates,” “plans,” “intends,” “believes” and variations of such words
or similar expressions that predict or indicate future events or trends, or
that do not relate to historical matters. These statements are based on our
current beliefs or expectations and are inherently subject to significant
uncertainties and changes in circumstances, many of which are beyond our
control. There can be no assurance that our beliefs or expectations will be
achieved. Actual results may differ materially from our beliefs or
expectations due to economic, business, competitive, market and regulatory
factors.
(footnote 1) A lower confidence bound of greater than 95% indicates that if
the study were repeated, there would be less than a 5% chance that the
sensitivity would be below 95%.
(footnote 2) A p-value of less than 0.05 indicates a less than 5%
probability that the observed difference was due to chance.
For further information contact:
Investors
David Carey
Lazar Partners Ltd.
212-867-1768
Email Contact
Media
Hollister Hovey
Lazar Partners Ltd.
646-871-8482
Email Contact

Bovie Medical Corporation Announces FDA 510(K) Clearance to Market …

admin — Mon, 27 Oct 2008 04:07:30 +0000

MELVILLE, N.Y., Nov 19, 2008 (BUSINESS WIRE) –
Bovie Medical Corporation (the “Company”) (NYSE Alternext US: BVX), a
manufacturer and marketer of electrosurgical products, today announced
the Company received 510(k) clearance from the Food and Drug
Administration (FDA) to market its SEER tissue resection device intended
for initial use in liver oncology surgery. The SEER device uses
conductive sintered steel as an electrode for radio frequency (RF) for
cutting and coagulation. The process involves delivery of RF current and
sterile saline for resection and coagulation in surgical procedures. The
Company anticipates developing additional products based on the SEER
technology for use in orthopedic and blood vessel sealing procedures.
The worldwide market size for the liver and orthopedic market is
expected to total $500 million in 2009.

Teva Announces FDA Approval and Commercial Launch of Fentanyl …

admin — Sun, 19 Oct 2008 20:26:27 +0000

Oct 20 2008, 12:23 PM EST
Teva Pharmaceutical Industries Ltd. (
) announced today
that the U.S. Food and Drug Administration has granted approval for
the Company’s Abbreviated New Drug Application (ANDA) for Fentanyl
Transdermal System, 25 mcg/hour, 50 mcg/hour, 75 mcg/hour and 100
mcg/hour, the AB-rated generic equivalent of Ortho McNeil’s chronic
pain treatment Duragesic(R). Shipment of this product has commenced.
Total annual sales of this product for the strengths noted above,
including both brand and generic sales, were approximately $1.2
billion in the United States for the twelve months that ended June 30,
2008, based on IMS sales data.
Teva’s Fentanyl Transdermal System was developed and manufactured
by Aveva Drug Delivery Systems, a Nitto Denko company, which is one of
the world’s largest manufacturers of, and a pioneer in, “drug in
adhesive” transdermal patch technology. The product utilizes a
proprietary matrix design which incorporates the drug into the
adhesive. It is indicated for the management of persistent moderate to
severe chronic pain that requires continuous, around-the-clock opioid
administration for an extended period of time and that cannot be
managed by other means such as non-steroidal analgesics, opioid
combination products, or immediate-release opioids.
FDA’s diligence in approving this ANDA ensures that patients
continue to have access to this medicine.
Teva Pharmaceutical Industries Ltd., headquartered in Israel, is
among the top 20 pharmaceutical companies in the world and is the
world’s leading generic pharmaceutical company. The Company develops,
manufactures and markets generic and innovative human pharmaceuticals
and active pharmaceutical ingredients, as well as animal health
pharmaceutical products. Over 80 percent of Teva’s sales are in North
America and Europe.
Aveva Drug Delivery Systems (www.avevadds.com) is a Nitto Denko
company, with a proven track record for providing pharmaceutical
partners with fully integrated, controlled-release transdermal
products. The company offers a pipeline of products for license along
with a full range of research, development and manufacturing
capabilities to produce proprietary and generic transdermal drug
delivery systems. For more information contact Robert J. Bloder at
(954)-624-1374.
Safe Harbor Statement under the U. S. Private Securities
Litigation Reform Act of 1995:
This release contains forward-looking statements, which express
the current beliefs and expectations of management. Such statements
are based on management’s current beliefs and expectations and involve
a number of known and unknown risks and uncertainties that could cause
our future results, performance or achievements to differ
significantly from the results, performance or achievements expressed
or implied by such forward-looking statements. Important factors that
could cause or contribute to such differences include risks relating
to: our ability to successfully develop and commercialize additional
pharmaceutical products, the introduction of competing generic
equivalents, the extent to which we may obtain U.S. market exclusivity
for certain of our new generic products and regulatory changes that
may prevent us from utilizing exclusivity periods, competition from
brand-name companies that are under increased pressure to counter
generic products, or competitors that seek to delay the introduction
of generic products, the impact of consolidation of our distributors
and customers, potential liability for sales of generic products prior
to a final resolution of outstanding patent litigation, including that
relating to the generic versions of Allegra(R) , Neurontin(R),
Lotrel(R) and Protonix(R), the effects of competition on our
innovative products, especially Copaxone(R) sales, the impact of
pharmaceutical industry regulation and pending legislation that could
affect the pharmaceutical industry, the difficulty of predicting U.S.
Food and Drug Administration, European Medicines Agency and other
regulatory authority approvals, the regulatory environment and changes
in the health policies and structures of various countries, our
ability to achieve expected results though our innovative R&D efforts,
our ability to successfully identify, consummate and integrate
acquisitions, including the pending acquisition of Barr
Pharmaceuticals Inc., potential exposure to product liability claims
to the extent not covered by insurance, dependence on the
effectiveness of our patents and other protections for innovative
products, significant operations worldwide that may be adversely
affected by terrorism, political or economical instability or major
hostilities, supply interruptions or delays that could result from the
complex manufacturing of our products and our global supply chain,
environmental risks, fluctuations in currency, exchange and interest
rates, and other factors that are discussed in this report and in our
other filings with the U.S. Securities and Exchange Commission
(“SEC”).

SXC Health Solutions announces contract with PharMerica

admin — Thu, 16 Oct 2008 20:14:00 +0000

- Agreement strengthens SXC’s lead in the Long-Term Care market -

LISLE, IL, Jan. 5 /PRNewswire-FirstCall/ – SXC Health Solutions Corp. (“SXC”
or the “Company”) (NASDAQ: SXCI, TSX: SXC), a leading provider of technology
and pharmacy benefit management services, announces that its Health Care
Information Technology business group has been awarded a three-year,
multi-million dollar contract to provide its Resident Care Management (RCM)
offering of technology and services to PharMerica Corporation (NYSE: PMC) of
Louisville, Kentucky.
Under terms of the agreement, PharMerica will receive SXC’s industry-leading
Long-Term Care (LTC) claims adjudication and RCM consulting services.
PharMerica operates more than 100 institutional pharmacies throughout the
U.S., and serves approximately 326,000 patient beds in LTC facilities.
“We are pleased to add another premier client such as PharMerica to our LTC
business,” said Mark Thierer, President and CEO of SXC. “The LTC market is
beginning to invest more heavily in advanced managed pharmacy services
creating a significant market opportunity for SXC. Our sophisticated
technology, broad clinical expertise and flexible service-delivery model make
us an innovative player that is well positioned to capture a significant share
of this developing market.”
“SXC’s RCM products are key elements in PharMerica’s plan to improve the
quality of our pharmacy services and deliver proven cost management
solutions,” said Greg Weishar, CEO at PharMerica. “The flexibility of SXC’s
technology and our ability to easily integrate RCM were critical factors in
choosing SXC.”

About PharMerica Corporation

PharMerica Corporation is an industry leading institutional pharmacy services
provider dedicated to providing quality customer service and innovative
pharmacy solutions to Long Term Care Providers and institutionalized long term
care patients. Headquartered in Louisville, Kentucky, PharMerica operates more
than 100 institutional pharmacies that serve over 326,000 patients as of
September 30, 2008. PharMerica has approximately 6,200 employees nationwide.
Additional information can be found at www.pharmerica.com.

About SXC Health Solutions Corp.

SXC Health Solutions Corp. is a leading provider of pharmacy benefits
management (PBM) services and Health Care Information Technology (HCIT)
solutions to the healthcare benefits management industry. The Company’s
product offerings and solutions combine a wide range of PBM services and
software applications, application service provider (ASP) processing services
and professional services, designed for many of the largest organizations in
the pharmaceutical supply chain, such as health plans, employers, Federal,
provincial, and, state and local governments, pharmacy benefit managers,
retail pharmacy chains and other healthcare intermediaries. SXC is
headquartered in Lisle, Illinois with 13 locations in the US and Canada. For
more information please visit www.sxc.com.

SOURCE SXC Health Solutions Corp.

Jeff Park, Chief Financial Officer, SXC Health Solutions Corp., Tel: (630)
577-3206, investors@sxc.com; Dave Mason, Investor Relations – Canada, The
Equicom Group Inc., (416) 815-0700 ext. 237, dmason@equicomgroup.com; Susan
Noonan, Investor Relations – U.S., The SAN Group, LLC, (212) 966-3650,
susan@sanoonan.com

Spinning(R) Announces First Heart Rate and Fitness Application for …

admin — Thu, 16 Oct 2008 15:08:37 +0000

The Spinning program offers an energizing, cycling-inspired group exercise
training program with expert coaching, exhilarating music and a unique
mind/body philosophy — all at a self-directed pace. The Spinning program has
reached more than 30,000 clubs and millions of enthusiasts in 80 countries
worldwide. Venice, California-based Mad Dogg Athletics, Inc. is the worldwide
leader in indoor group cycling bikes, education and products. The company
works closely with Star Trac(R) on its patented line of Spinner bikes and
develops and markets Spinning instructor orientations, continuing education
programs and offers a complete line of Spinning branded apparel and
accessories. For more information about Mad Dogg Athletics, Inc. and the
Spinning program, visit
. iSPINNING(TM) is a trademark
and Spin(R), Spinning(R), Spinner(R) and the Spinning logo are registered
trademarks of Mad Dogg Athletics, Inc.